Low-grade gliomas (LGGs) represent an important yet somewhat neglected category of brain tumors. Animal models are lacking, and these precursors of secondary glioblastomas were not studied in the Cancer Genome Atlas Project. Moreover, as median survival is at least several years and in some subtypes greater than a decade, these tumors are less amenable to clinical trials than their high-grade counterparts. Nonetheless, the past decade has seen important advances in imaging techniques and our understanding of molecular underpinnings and the role of chemotherapy. Thus, the time is ripe for a comprehensive review.
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Particular strengths of Dr. Sanai and coauthors' 12 excellent article include the discussion of mapping, tumor surgery, and surgical management of tumor-associated epilepsy as well as the thorough assessment of newer imaging techniques including metabolic imaging with MR spectroscopy and PET. Overviews of epidemiology and molecular/chromosomal abnormalities are informative and au courant.
With the surfeit of potential molecular and genetic markers discussed (including p53, PDGF/R, 1p/19q, MGMT status, IDH mutational status), how does the clinician ascertain which have prognostic import or help predict response to specific therapies? A recent review assessed the clinical utility of readily available assays. 1 Most studies suggest that 1p/19q codeletion is a favorable prognostic factor in LGG with significant impact on both overall and progression-free survival-information important to clinicians and patients. Less clear is whether 1p/19q codeletion predicts a favorable response of LGGs to PCV (procarbazine/CCNU/vincristine) or temozolomide chemotherapy; while results are mixed, the majority of studies do not show differential response. Moreover, in both the newly diagnosed and recurrent settings, non-codeleted LGGs sometimes respond favorably to PCV and temozolomide. Consequently, as Sanai and colleagues 12 indicate, 1p/19q status should not be utilized as a rigid litmus test to determine the role and timing of chemotherapy.
Fewer data support the value of MGMT promoter methylation testing in LGG. We know that MGMT promoter methylation is a favorable prognostic factor in both glioblastoma and anaplastic oligodendrogliomas; 20 it does not predict chemosensitivity in anaplastic oligodendrogliomas but appears to do so in glioblastoma. 5 The strong correlation between 1p/19q codeletion and MGMT promoter methylation makes it difficult to tease out the independent contribution of MGMT in LGG. Thus far, although univariate studies suggest a favorable impact of promoter methylation on overall survival, 18 multivariate studies have not confirmed this. While an earlier study suggested promoter methylation predicted LGG chemosensitivity, subsequent studies have failed to confirm this. 7, 18 Consequently, I do not routinely assay MGMT status in LGGs.
Compelling data support the conclusion that IDH mutations are associated with improved survival in LGG. 6, 13, 18 As with MGMT, there is a strong correlation between IDH mutation and 1p/19q codeletion; almost all codeleted tumors are IDH-mutated. Moreover, IDH mutation and MGMT promoter methylation are themselves highly correlated in LGG. 18 Nonetheless, IDH mutation also conveys a favorable prognosis in LGGs that are not codeleted. Data are conflicting as to whether IDH mutations predict chemosensitivity. 4, 6, 18 As IDH1 mutations can be readily detected "in house" with immunohistochemistry and convey prognostic information, we routinely test for these in LGG.
Since
LGGs have such a wide range of outcome, prognostic tools are very useful for clinicians counseling patients. Chang's work underlying the University of California at San Francisco (UCSF) Low-Grade Glioma Prognostic Scoring System showed that increasing tumor size and location in eloquent brain are adverse prognostic factors. 2 The data supporting aggressive resection of LGG are suboptimal and at best represent Level II (b) evidence. For example, patients with extensive resection might do better than those undergoing biopsy because the former are less likely to have undersampled regions of anaplastic glioma, which itself confers a worse prognosis. Moreover, patients undergoing biopsy were excluded from the large, carefully reported UCSF series that showed increasing extent of resection and smaller preoperative and postoperative tumor volume correlate with improved survival.
opinion that "observation of LGGs is not a prudent option and early tissue diagnosis is essential." Patients with suspected LGGs with favorable factors (young age, small tumors, radiological features suggesting oligodendroglioma, asymptomatic or well-controlled seizures) are widely seen as reasonable candidates for observation with deferral of potential surgical morbidity. 17 Close MR imaging surveillance mitigates the risk of uncontrolled growth and anaplastic transformation, although the recognition that LGGs grow in a continuous fashion suggests this approach at best delays the inevitable. 10, 11 Finally, the relatively brief sections on radiotherapy and chemotherapy deserve some amplification, in particular the evidence base for postsurgical LGG therapy. 15 Consistent with the review's flow chart of recommended treatment, RTOG 9802 strongly supports observation for LGG patients with MR imaging-confirmed gross-total resection. However, the blanket recommendation of temozolomide over radiotherapy as initial treatment for
LGGs not amenable to gross-total resection is not discussed in detail and will undoubtedly ruffle some feathers. What are the options and the data regarding optimal initial postsurgical treatment?
Fractionated radiotherapy is of proven benefit for LGGs, improving progression-free survival by 2 years on average. Moreover, approximately one-third of patients achieve a radiological partial response, a higher figure than is generally reported for temozolomide or PCV chemotherapy. That data showing improved overall survival with fractionated radiotherapy are lacking reflects the fact that no trial permanently withholding radiation therapy from one arm could ethically be conducted. Therefore, the question regarding radiation therapy is not "whether" but "when." The principal reason to defer radiation therapy is concern for producing cognitive neurotoxicity, which has both acute and delayed components. Somewhat reassuringly, a decade ago a cohort study in LGG patients a mean of 6 years postradiotherapy demonstrated that with radiation fractions of 200 cGy or less daily the tumor and anticonvulsants were much more important causes of cognitive decline that the effects of radiotherapy. 8 Recent follow-up of this cohort indicates more significant cognitive decline at a mean duration of 12 years since diagnosis. 3 While these data are concerning and support delaying radiation therapy when feasible in patients with relatively long anticipated survival, it is important to realize patients in this study received their radiation therapy in the 1970s to 1990s. Total radiation doses were higher and radiation fields often larger during that epoch. It is highly likely improved radiation planning and the recognition that total doses above 4500-5000 cGy are of no benefit have decreased this risk. Further careful studies of radiation's long-term effects are sorely needed.
What data support chemotherapy as the initial postsurgical therapy for LGGs? Several small studies with temozolomide suggest a radiographic response rate between 31% and 61% if "minor responses" (tumor shrinkage of 25%-50%) are included; rates for strictly defined partial responses (50%-99% tumor reduction) are on the order of 20%. 14 The median time to tumor progression ranges from approximately 30 to 48 months. While these figures are similar to results seen with fractionated radiotherapy, patient numbers are small. The results from European Organization for Research and Treatment of Cancer (EORTC) 22033/26033, in which patients with LGGs were randomized to temozolomide versus radiation, will provide clear data on response rates and progression-free survival with chemotherapy. It will also indicate whether 1p deletion status is a determinant of optimal therapy. The chief potential benefit of temozolomide over fractionated radiotherapy is the lack of long-term cognitive neurotoxicity with the former. As EORTC 22033/26033 has quality-of-life and neurocognitive components, it promises to provide information regarding the magnitude of any such benefit. Until further data are available, either radiation or temozolomide represents a reasonable initial management strategy for LGGs. Patients with tumors expected to behave aggressively (for example, those with advancing age or 1p/19q intact without IDH mutation) probably have little to gain by deferring radiation; temozolomide therapy might make more sense in patients with a confluence of favorable prognostic variables.
Recognizing that LGGs are malignant tumors that are almost always fatal, is there a role for more aggressive therapy by combining radiation and chemotherapy? As Sanai et al. 11 note, the combination of radiation and PCV chemotherapy did not improve survival compared to initial therapy of radiation alone with chemotherapy at progression. The combination of radiation and temozolomide for high-risk LGGs is now under study. The Radiation Therapy Oncology Group (RTOG) recently finished accrual to a Phase II study (RTOG 0424) of this combination. The major US cooperative brain tumor groups (the Eastern Cooperative Oncology Group [ECOG], the North Central Cancer Treatment Group [NCCTG] , and the RTOG) recently launched a Phase III trial (ECOG E3F05) in which patients with LGGs are randomized to radiation plus temozolomide or radiotherapy alone. Designed similarly to EORTC 22033/26033, it incorporates neurocognitive testing and quality-of-life assessments and should ultimately provide information regarding the potential benefit of "temoradiation" in LGG.
At present, the multitude of reasonable options in the absence of definitive trials makes advising patients with
LGGs more challenging and time-consuming than advising those with high-grade gliomas. One hopes the ongoing Phase III trials clarify the optimal timing of temozolomide treatment while the research discussed in Sanai and colleagues' review 12 leads to promising new therapies. Clinical trial design for LGGs will need to evolve to do justice to the complexities of determination of imaging and to incorporate end points of neurocognitive function and quality of life that are as relevant as the traditional end points of overall and progression-free survival.
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Disclosure Dr. Schiff has received an honorarium from Schering-Plough for an educational lecture and is the study chair of ECOG E3F05, which evaluates the role of temozolomide with radiation for lowgrade glioma.
I greatly appreciate the comment made by Dr. David Schiff regarding our manuscript "Low-grade gliomas in adults." Dr. Schiff has made significant contributions toward our understanding of the biology and treatment of
LGGs as well as outcome for patients with these difficultto-manage gliomas. Thus, his insight is particularly valuable and important for anyone who takes care of patients with LGGs. Perhaps the single most controversial issue in the treatment paradigm of adults with LGGs is whether to radiate the residual mass following the initial surgery when a complete radiographic resection is not possible. As we demonstrate in our review, and as is confirmed by Dr. Schiff's comments regarding the experience from our European colleagues as well as North American neurooncologists, there appears to be little if any advantage to utilizing radiation following surgery in the up-front setting other than perhaps to delay progression. The more interesting question is whether for high-risk patients-for example, those older than 45 years of age or with tumors larger than 4-6 cm, astrocytic histology, or eloquent tumor location resulting in a partial resection-radiation should be added to temozolomide as opposed to just treating with chemotherapy. While we may know this answer in the near future, for now, I will continue to recommend temozolomide for patients with incompletely resected
LGGs regardless of risk status and hold off radiation until radiological and/or symptomatic progression occurs.
